Haisco Pharmaceutical Group's (SHE:002653) subsidiary, Shanghai Hisun Pharmaceutical Technology, received approval from China's National Medical Products Administration to conduct clinical trials on four drugs, according to a Wednesday filing on the Shenzhen bourse.
The drugs are the HSK45019 tablets, HSK50042 tablets, HSK55718 injection and HSK36357 capsules, which will be tested as a treatment for inflammatory bowel disease, respiratory diseases, acute pain and muscular dystrophy, respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments